1

                                                                    EXHIBIT 99.1

                             [FORM OF PRESS RELEASE]

    ECLIPSE SURGICAL TECHNOLOGIES CHANGES NAME TO CARDIOGENESIS FOLLOWING
 APPROVAL BY SHAREHOLDERS AT ANNUAL MEETING RELOCATING TO SOUTHERN CALIFORNIA
 FROM SILICON VALLEY

        SUNNYVALE, Calif., Jun 18, 2001 -- Eclipse Surgical Technologies
(Nasdaq: ESTI), a leading medical device company specializing in myocardial
revascularization systems, announced today that its shareholders voted to change
the Company's name to CardioGenesis Corporation at its Annual Meeting of
Shareholders held as scheduled Friday, June 15, 2001, in Santa Clara, CA. A
quorum of shareholders was present in person or by proxy at the Meeting and all
proposals submitted to the shareholders were approved, including the re-election
of the Company's five Directors and the amendment to the Company's Restated
Articles of Incorporation to change the Company's name.

        The change of name to CardioGenesis Corporation, which is the name of
the company Eclipse acquired in March 1999, is expected to become effective
today, June 18, 2001. The Company anticipates that the trading symbol of its
common stock on the Nasdaq National Market will be changed from ESTI to CGCP,
effective with the opening of the market on Thursday, June 21, 2001.

        CardioGenesis also announced at its Shareholder meeting that it is
moving its corporate headquarters from the Silicon Valley to a more economical
location in Southern California. the move to its new offices in Foothill Ranch,
CA is expected to be completed before the end of August this year.

        Chairman, President and CEO Michael J. Quinn commented, "CardioGenesis
better reflects the new, expanded vision that the Company has adopted. Today
we're a revitalized company with a clearly defined mission. We are committed to
becoming profitable, taking full advantage of our current products and
technologies and expanding our product offering to treat a broader range of
cardiovascular disease.

        "We started implementing our new vision by increasing our focus on the
patients who suffer from angina," Quinn added. "This can be seen through our
company-wide commitment to take full advantage of the potential of our
industry-leading TMR (Transmyocardial Revascularization) surgical system and to
successfully launch our new minimally invasive PMR (Percutaneous Myocardial
Revascularization) system, which we are hopeful will be cleared to market by the
U.S. Food and Drug Administration (FDA) later this year." The FDA has scheduled
a meeting of its Circulatory System Devices Panel on July 9 to review the
Company's supplemental Premarket Approval application for PMR.

        PMR is a catheter-based procedure in which a cardiologist gains access
to the heart through the femoral artery and then uses the Company's laser to
create tiny holes in the heart muscle that are believed to stimulate the growth
of new blood vessels (angiogenesis).



   2

        After it hopefully obtains FDA clearance to market PMR, CardioGenesis
intends to begin to expand its product line. The Company will seek to add
complementary products for the treatment of cardiovascular disease that fit well
into its distribution model. This could include delivery systems for growth
factor compounds that stimulate the body's production of new blood vessels in
the heart, as well as other innovative products for surgical and percutaneous
cardiac applications. The Company expects to expand its offerings, both
domestically and internationally, through a variety of means, which may include
distribution agreements, licensing, acquisitions and/or internal development.

        Since Quinn joined the Company eight months ago, it has implemented a
new far-reaching vision, revamped its sales and marketing organizations and
taken important steps to get its expenses in line with revenue. "This has meant
making some tough decisions and implementing a number of dramatic changes
throughout the Company," Quinn said. "If needed, we will continue to make
changes to ensure we are positioned to take full advantage of opportunities for
increasing growth and profitability. The move from the high rents and labor
costs of the Silicon Valley to the more business friendly costs of our new
location in Orange County is another important example of how we intend to get
our operating expenses in line and keep them there."

        At the Annual Meeting of Shareholders, the shareholders also approved:
The appointment of PricewaterhouseCoopers LLP as the Company's independent
auditors for the fiscal year ending December 31, 2001; an amendment to the
Company's Stock Option Plan to increase the number of shares of Common Stock
reserved for issuance under the Plan by 500,000 shares; and an amendment to the
Company's Employee Stock Purchase Plan to increase the number of shares of
Common Stock reserved for issuance under that Plan by 300,000 shares.

        The Directors re-elected to serve until the next Annual Meeting of
Shareholders or until their successors are elected and qualified are: Michael J.
Quinn, 56, the Company's Chief Executive Officer, President and Chairman of the
Board; Jack M. Gill, 65, Ph.D., a founding general partner of Vanguard Venture
Partners and formerly Chairman of the Board of Directors of CardioGenesis
Corporation, which the Company acquired in March 1999; Alan L. Kaganov, Sc.D.,
62, a Venture Partner at U.S. Venture Partners and previously the Company's
Chief Executive Officer; Robert L. Mortensen, 66, has served as either President
or Chairman of the Board and a Director of Lightwave Electronics Corporation, a
solid-state laser company he founded; and Robert C. Strauss, 59, President and
Chief Executive Officer of Noven Pharmaceuticals, Inc.

        About CardioGenesis Corporation:

        CardioGenesis, formerly Eclipse Surgical Technologies, is a medical
device company specializing in the treatment of cardiovascular disease and is
the leader in products that stimulate cardiac angiogenesis. The Company's
market-leading Holmium YAG laser system and disposable fiber-optic accessories
are used to perform a FDA-cleared surgical procedure known as transmyocardial
revascularization (TMR) to treat patients suffering from angina. The
CardioGenesis TMR procedure, which is marketed in the U.S., Europe and Asia, has
been shown to reduce angina and improve the quality of life in patients with
coronary artery disease.



   3

        CardioGenesis submitted a Premarket Approval Application (PMA) to the
FDA in December 1999 for a minimally invasive, catheter-based version of the
procedure, called percutaneous myocardial revascularization (PMR), and a FDA
panel is scheduled to review the PMA in a meeting on July 9, 2001. The Company's
PMR device is currently being marketed in selected countries in Europe, after
having received a CE mark.

        For more information on the Company and its products, please visit the
CardioGenesis web site at http://www.eclipsesurg.com. for investor relations
information, visit the CardioGenesis pages in the "Client" section of the Allen
& Caron Inc web site at www.allencaron.com

        Any forward-looking statements in this news release related to the
Company's sales, profitability and the adoption of its technology and products
are based on current expectations and beliefs and are subject to numerous risks
and uncertainties that could cause actual results to differ materially. Other
factors that could cause Eclipse's actual results to differ materially are
discussed in the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2000 and the Company's other recent SEC
filings. The Company disclaims any obligation to update any forward-looking
statements as a result of developments occurring after the date of this press
release.